Skip to main content
. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787

Fig. 4.

Fig. 4

Frequency and severity of (a) 13 viral illness long COVID symptoms and (b) 14 additional long COVID symptoms reported in participant long-term diary at week 36 by participants who received Amubarvimab/romlusevimab (A/R) (n = 339) or Placebo (n = 312).